The Australian Patent Office (APO) has issued a decision finding that ProQR Therapeutics II B.V.'s RNA editing antisense oligonucleotide claims are invalid for lack of sufficiency and support due to broad functional limitations and "unbridled" medical use claims in Wrays Solutions Pty Ltd v ProQR Therapeutics II B.V. [2026] APO 36 . The decision demonstrates that the APO's approach to broad functional claiming is largely aligned with that in Europe and other major jurisdictions, while the approach to medical use claims reflects an arguably stricter standard that may require additional limitations to be sufficiently enabled. Brief background The claims at issue relate to chemically modified antisense oligonucleotides ( AON s) that recruit a cell’s naturally occurring ADAR enzyme to achieve conversion of a target adenosine to inosine ( A-to-I editing ) in RNA by modifications in a "Central Triplet" of three sequential nucleotides. The claimed modifi...